Related references
Note: Only part of the references are listed.Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
Anita Kulukian et al.
MOLECULAR CANCER THERAPEUTICS (2020)
In vivo efficacy studies of novel quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors, in lung cancer xenografts (NCI-H1975) mice models
Debasis Das et al.
BIOORGANIC CHEMISTRY (2020)
Biologicals to direct nanotherapeutics towards HER2-positive breast cancers
Gautam Kumar et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2020)
A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer
Vikas Jain et al.
JOURNAL OF CONTROLLED RELEASE (2020)
The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
Takashi Nakada et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2019)
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
Gabriel Rinnerthaler et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry
Debasis Das et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer
Marco Mazzotta et al.
JOURNAL OF CLINICAL MEDICINE (2019)
[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model
Tomomi Nakayama Iwata et al.
PLOS ONE (2019)
Discovery of new quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors and their anticancer activities - Part 1
Debasis Das et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys
Yoko Nagai et al.
XENOBIOTICA (2019)
Docetaxel-loaded nanostructured lipid carriers functionalized with trastuzumab (Herceptin) for HER2-positive breast cancer cells
Jaleh Varshosaz et al.
JOURNAL OF LIPOSOME RESEARCH (2018)
Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions
Francesca Battaglin et al.
CANCER CELL INTERNATIONAL (2018)
Recent Insights into the Development of Preclinical Trastuzumab-Resistant HER2+Breast Cancer Models
Paula Gonzalez-Alonso et al.
CURRENT MEDICINAL CHEMISTRY (2018)
Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors
Chia-Yu Su et al.
DRUG DELIVERY (2018)
A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model
Tomomi Nakayama Iwata et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer
Xin Li et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance
Naoki Takegawa et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
Toshihiko Doi et al.
LANCET ONCOLOGY (2017)
Strategies and challenges for the next generation of antibody drug conjugates
Alain Beck et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment
Shanshan Deng et al.
CURRENT MEDICINAL CHEMISTRY (2017)
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer
Xiaowei Xu et al.
CLINICAL CANCER RESEARCH (2017)
Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells
Hongbin Wang et al.
CANCER SCIENCE (2017)
Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads
Takashi Nakada et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
Yusuke Ogitani et al.
CANCER SCIENCE (2016)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing
Wayne C. Widdison et al.
BIOCONJUGATE CHEMISTRY (2015)
HER2-Mediated Anticancer Drug Delivery: Strategies to Prepare Targeting Ligands Highly Specific for the Receptor
Enrica Calce et al.
CURRENT MEDICINAL CHEMISTRY (2015)
Targeted Anti-HER2 Cancer Therapy in Elderly Women Diagnosed with Breast Cancer
M. J. Molina-Garrido et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2014)
Trastuzumab emtansine: mechanisms of action and drug resistance
Mark Barok et al.
BREAST CANCER RESEARCH (2014)
Ado-trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer
John M. Lambert et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
Sven Golfier et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Pertuzumab: new hope for patients with HER2-positive breast cancer
M. Capelan et al.
ANNALS OF ONCOLOGY (2013)
Synthesis, structure analysis, antitumor evaluation and 3D-QSAR studies of 3,6-disubstituted-dihydro-1,2,4,5-tetrazine derivatives
Guo-Wu Rao et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer
Nadia Harbeck et al.
BREAST CARE (2013)
Antibody-Drug Conjugates for the Treatment of Cancer
John A. Flygare et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2013)
Synthesis, Antitumor Evaluation and Docking Study of Novel 4-Anilinoquinazoline Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors
Guo-Wu Rao et al.
CHEMMEDCHEM (2013)
Trastuzumab Emtansine: First Global Approval
Anita Ballantyne et al.
DRUGS (2013)
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers
Helena A. Yu et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability
Kirsten Achilles Poon et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2013)
Synthesis, Structure Analysis, and Antitumor Evaluation of 3,6-Dimethyl-1,2,4,5-tetrazine-1,4-dicarboxamide Derivatives
Guo-Wu Rao et al.
CHEMMEDCHEM (2012)
MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells
Chin-Tung Chen et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies
Sara A. Hurvitz et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2012)
Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
Flavio Solca et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
Teemu T. Junttila et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer
Howard A. Burris
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
The resurgence of covalent drugs
Juswinder Singh et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo
Mark Barok et al.
BREAST CANCER RESEARCH (2011)
Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody-Maytansinoid Conjugates
Hans K. Erickson et al.
BIOCONJUGATE CHEMISTRY (2010)
Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Microtubules and resistance to tubulin-binding agents
Maria Kavallaris
NATURE REVIEWS CANCER (2010)
Design, Synthesis, and Biological Evaluation of Antibody-Drug Conjugates Comprised of Potent Camptothecin Analogues
Patrick J. Burke et al.
BIOCONJUGATE CHEMISTRY (2009)
Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
Li Liu et al.
CANCER RESEARCH (2009)
Targeted cancer therapy: Conferring specificity to cytotoxic drugs
Ravi V. J. Chari
ACCOUNTS OF CHEMICAL RESEARCH (2008)
The development of HKI-272 and related compounds for the treatment of cancer
Allan Wissner et al.
ARCHIV DER PHARMAZIE (2008)
Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
Pieter J. A. Eichhorn et al.
CANCER RESEARCH (2008)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation
Torsten Trowe et al.
CLINICAL CANCER RESEARCH (2008)
Discovery of novel small-molecule inhibitors of human epidermal growth factor receptor-2: Combined ligand and target-based approach
Rambabu Gundla et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
D. Li et al.
ONCOGENE (2008)
Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors
Yoshinobu Shiose et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2007)
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB Ligands and remain dependent on the ErbB receptor network
Christoph A. Ritter et al.
CLINICAL CANCER RESEARCH (2007)
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272
Y. Minami et al.
ONCOGENE (2007)
Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series
Kimberly G. Petrov et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab
CW Adams et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
HK Erickson et al.
CANCER RESEARCH (2006)
2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth
N Takai et al.
CANCER (2005)
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
EL Kwak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity
HR Tsou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
Synthesis and SAR of potent EGFR/erbB2 dual inhibitors
YM Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin
CD Austin et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase
SK Rabindran et al.
CANCER RESEARCH (2004)
Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines
MD Gaul et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
HS Cho et al.
NATURE (2003)
The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors
TPJ Garrett et al.
MOLECULAR CELL (2003)
Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)
A Wissner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
A new anti-ErbB2 strategy in the treatment of cancer: Prevention of ligand-dependent ErbB2 receptor heterodimerization
J Baselga
CANCER CELL (2002)
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
DB Agus et al.
CANCER CELL (2002)
Tumor biology - Herceptin acts as an anti-angiogenic cocktail
Y Izumi et al.
NATURE (2002)
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
YH Lu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity
HR Tsou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2
S Cockerill et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
Thrombospondins as matricellular modulators of cell function
P Bornstein
JOURNAL OF CLINICAL INVESTIGATION (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
4-Anilino-6,7-dialkoxyquinolime-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors
A Wissner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Share Paper
